Vaccine Contract Manufacturing Companies

Published: October 2024

Vaccine contract manufacturing refers to manufacturing services that are provided by contract manufacturers to pharmaceutical product developers for the large-scale production of vaccines. The increasing pipeline of vaccines targeting various infectious diseases, oncological and autoimmune disorders drives the demand for contract manufacturing services, especially for specialized vaccines such as mRNA and viral vector vaccines. We analyzed over 230 contract manufacturers that are engaged in offering manufacturing services to vaccine developers, across the globe. In this article, discover top five vaccine contract manufacturing companies and their capabilities.

The rise of FDA-approved vaccines and ongoing scientific advancements signals the transition of pharmaceutical companies towards a new era of vaccines. With the rising demand for vaccines, opportunities for contract manufacturing organizations (CMOs) specializing in vaccines are growing steadily. Since 2000, more than 130 vaccine CMOs have been established, reflecting the market expansion of contract service providers. Contract service providers have been focusing on increasing in-house capabilities to offer a wider range of services to their clients, along with regulatory assistance. Competition among CMOs is intense, with access to cutting-edge tools and technologies being a crucial differentiator. Consequently, CMOs are expanding their capacities and capabilities to consolidate their positions in the market and meet the escalating demand for vaccines. With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for vaccine contract manufacturing is expected to witness remarkable growth during the forecast period.

Roots Analysis has conducted an exhaustive study on Vaccine Contract Manufacturing Market featuring the current market landscape and future opportunity for the companies engaged in offering vaccine manufacturing services across the globe, over a span of 11 years.

Below, we have listed (in alphabetical order), the top 5 vaccine contract manufacturing companies:

Boehringer Ingelheim BioXcellence
Catalent
Charles River Laboratories
Insud Pharma
Lonza

Top Vaccine Contract Manufacturing Companies

Interested in exploring all 230+ vaccine contract manufacturing companies and their recent initiatives?

Discover Below the Details on Top 5 Vaccine Contract Manufacturing Companies

Let us deep dive to understand the activity of the top 5 vaccine contract manufacturing companies (very large companies having service portfolio strength score, more than or equal to 28, based on our proprietary company competitiveness matrix). It is essential to note that the selection of top players can differ substantially according to the defined criteria.

In 2024, Boehringer Ingelheim BioXcellence Received the CDMO Leadership Award in All Six Categories, namely Capabilities, Compatibility, Expertise, Quality, Reliability and Service

1. Boehringer Ingelheim BioXcellence

Boehringer Ingelheim BioXcellence operates as the contract manufacturing division of Boehringer Ingelheim. The firm offers a wide range of services that cover various stages of the biopharmaceutical development process, including cell line and strain development, process development, and large-scale manufacturing. By leveraging its expertise in upstream and downstream processing, the firm facilitates the production of antibodies, recombinant proteins, non-antibody scaffolds, fragment antigen binding (Fab) fragments, and plasmid DNA through mammalian cell culture and microbial fermentation systems. In addition, it offers aseptic fill and finish services for freeze-dried products and liquid formulations. With more than 35 years of experience in the field of biotechnology, the firm has facilitated the commercialization of over 40 therapeutic modalities.

Boehringer Ingelheim BioXcellence: Company Overview

Key Parameters	Description
Company Logo
Year of Establisment	1885
Number of Employees	10,001+
Headquarters	Ingelheim am Rhein, Germany

Boehringer Ingelheim BioXcellence has been actively expanding its facilities and capabilities in the contract manufacturing market. The company has inaugurated its biologics manufacturing facility in Vienna, Austria with 185,000 bioreactor capacity to support both its own products and its CDMO business.

Further details on recent initiatives taken by Boehringer Ingelheim BioXcellence and other vaccine contract manufacturing companies have been provided in detail in the report.

Merger of Catalent with Novo Holdings Stands to Create Opportunities for Other CMOs

2. Catalent

Catalent offers development solutions and advanced delivery technologies for drugs, biologics, and consumer health products. Catalent was founded in April 2007, post-acquisition of the Pharmaceutical Technologies and Services segment of Cardinal Health by The Blackstone Group. The company employs more than 1,000 scientists at around 30 sites across the globe. With respect to pharmaceuticals, Catalent claims to have experience in working on more than 400 antibodies and 60 recombinant proteins. Moreover, it offers a comprehensive range of services, including formulation development, preclinical, clinical and commercial manufacturing, packaging, and advanced delivery technologies. The company’s expertise extends to various dosage forms, such as oral, injectable, inhalable, and topical medications.

Under an agreement with Novo Holdings in February 2024, the company will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion. The transaction is aimed at providing additional manufacturing capacity to Novo for GLP-1 manufacturing.

Catalent: Company Overview

Key Parameters	Description
Company Logo
Year of Establisment	2007
Number of Employees	10,001+
Headquarters	New Jersey, US

For instance, in August and June 2023, the company appointed Lisa Evoli as the Chief Human Resources Officer and Senior Vice President, and Matti Masanovich as the Chief Financial Officer and Senior Vice President, respectively. In the coming years, the firm is likely to recruit other eminent personalities to its management team in order to augment its thought leadership to pave way for future growth.

Further details on recent initiatives taken by Catalent and other vaccine contract manufacturing companies have been provided in detail in the report.

Charles River Laboratories is Focusing on Minimizing its Costs, as the Demand for Contract Services Declined Post Pandemic

3. Charles River Laboratories

Charles River Laboratories is a US-based CDMO, which claims to provide services to pharmaceutical companies, biotechnology companies, government agencies, hospitals and academic institutions, worldwide. The company primarily focuses on basic research, drug discovery, development and manufacturing services, conducting safety and efficacy studies, and providing clinical support across a wide range of therapeutic areas.

In June 2022, Charles River Laboratories collaborated with Ziphius to support the manufacturing of latter’s saRNA-based vaccine. Charles River will provide plasmid manufacturing services for the vaccine.

Charles River Laboratories: Company Overview

Key Parameters	Description
Company Logo
Year of Establisment	1947
Number of Employees	10,001+
Headquarters	Massachusetts, US

In January 2023, Charles River Laboratories launched eXpDNA plasmid manufacturing platform to optimize plasmid development and manufacturing timelines for cell therapy, gene therapy and nucleic acid vaccine developers.

Further details on recent initiatives taken by Charles River Laboratories and other vaccine contract manufacturing companies have been provided in detail in the report.

Insud Pharma’s mAbxience Buenos Aires Facility has a Capacity of 16,000L, Dedicated to the Production of Monoclonal Antibodies and Vaccines

4. Insud Pharma

Insud Pharma is a global pharmaceutical company headquartered in Madrid, specializing in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and branded pharmaceuticals for human and animal health. With a presence in over 96 countries, the company operates 18 manufacturing facilities and 15 R&D centers. Organized into three business units—Industrial (Chemo), Branded (Exeltis), and Biotech (mAbxience), Insud Pharma focuses on innovation and sustainable development to provide affordable access to quality medicines and improve health outcomes worldwide.

Insud Pharma: Company Overview

Key Parameters	Description
Company Logo
Year of Establisment	1977
Number of Employees	5,001-10,000
Headquarters	Madrid, Spain

In March 2023, the company collaborated HIPRA to enhance access to the BIMERVAX COVID-19 vaccine across Europe and Latin America.

Further details on recent initiatives taken by Insud Pharma and other vaccine contract manufacturing companies have been provided in detail in the report.

Lonza Has Actively Supported Several Vaccine Developers Over the Years and is Continuing to Build its Capabilities for Manufacturing of Novel Biologics

5. Lonza

Lonza claims to be one of the leading players in the biopharmaceutical contract manufacturing market. It offers a wide range of products and services, such as R&D and manufacturing services, to the pharmaceutical, healthcare and life science industries, and various academic and government research institutes. The company also provides services to the manufacturers, distributors, and formulators of consumer health products. It is worth noting that the company operates through nearly 90 sites and offices located in over 30 countries, across the world.

In October 2023, Lonza entered into a collaboration with Vaxcyte in order to manufacture broad-spectrum pneumococcal conjugate vaccines, named VAX-24 and VAX-31. During COVID pandemic, Lonza supported Moderna by manufacturing drug substance for mRNA vaccine at its Visp, Switzerland and Geleen, Netherlands facilities.

Lonza: Company Overview

Key Parameters	Description
Company Logo
Year of Establisment	1897
Number of Employees	10,001+
Headquarters	Basel, Switzerland

In October 2024, the company completed acquisition of the Genentech large-scale biologics manufacturing facility in California, US from Roche for USD 1.2 billion.

Further details on recent initiatives taken by Lonza and other vaccine contract manufacturing companies have been provided in detail in the report.

What About the Other Vaccine Contract Manufacturing Companies Around the World?

The above presentation features top 5 vaccine contract manufacturing companies selected from a pool of over 230 contract manufacturers that we have presented in our report. If you're interested, you can download the sample pages on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources